FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera, and GVHD Treatment

Key Takeaways

• FDA approves Jakafi XR extended-release formulation for three distinct conditions: myelofibrosis, polycythemia vera, and graft-versus-host disease
• Extended-release tablets may improve patient compliance through reduced dosing frequency compared to immediate-release Jakafi
• Approval extends Incyte’s successful ruxolitinib franchise and strengthens competitive position in JAK inhibitor market

---

WILMINGTON, Del. — Incyte Corporation (Nasdaq: INCY) announced today that the U.S. Food and Drug Administration has approved Jakafi XR™ (ruxolitinib) extended-release tablets, marking a significant expansion of the company’s JAK inhibitor portfolio.

Approved Indications

The FDA approval covers three distinct patient populations:

• Myelofibrosis: Adults with intermediate- or high-risk myelofibrosis, a rare bone marrow cancer
• Polycythemia Vera: Adults who have had inadequate response to or cannot tolerate hydroxyurea treatment
• Graft-Versus-Host Disease: Adults and children aged 12 years and older with steroid-refractory acute or chronic GVHD

Clinical Significance

Jakafi XR represents an extended-release formulation of ruxolitinib, a JAK1/JAK2 inhibitor that has been a cornerstone treatment for myeloproliferative neoplasms since the original Jakafi received FDA approval in 2011. The extended-release formulation is designed to provide similar efficacy with potentially improved dosing convenience.

“This approval offers patients and healthcare providers an additional treatment option that may enhance medication adherence through simplified dosing,” said pharmaceutical analysts following the announcement.

Market Impact and Competitive Landscape

The approval strengthens Incyte’s position in the competitive JAK inhibitor market, where the company faces competition from Novartis’s fedratinib and emerging therapies from Bristol Myers Squibb and AbbVie. The extended-release formulation serves as a life cycle management strategy, potentially protecting market share as patent exclusivity periods approach.

For myelofibrosis patients, treatment options remain limited, with JAK inhibitors representing the primary targeted therapy approach. The disease affects approximately 1-2 per 100,000 people annually, making it a rare but serious condition requiring specialized treatment.

Regulatory Pathway and Development

Jakafi XR followed a standard FDA approval pathway, building on the extensive clinical data supporting immediate-release ruxolitinib. The extended-release formulation required bioequivalence studies and formulation-specific safety data to demonstrate comparable efficacy and safety profiles.

The inclusion of pediatric GVHD patients aged 12 and older represents an important expansion, as treatment options for younger patients with this serious transplant complication are particularly limited.

Future Implications

This approval positions Incyte to maintain its leadership in the myeloproliferative neoplasm treatment space while potentially expanding patient access through improved dosing convenience. Healthcare providers now have additional flexibility in treatment planning, particularly for patients who may benefit from extended-release formulations.

The pharmaceutical industry continues to recognize the value of life cycle management strategies, with extended-release formulations offering meaningful benefits for chronic conditions requiring long-term treatment adherence.

Incyte expects to provide additional details regarding commercial availability and pricing in subsequent communications to healthcare providers and patients.

---

Frequently Asked Questions

What is the difference between Jakafi and Jakafi XR?

Jakafi XR is an extended-release formulation of the same active ingredient (ruxolitinib) found in regular Jakafi, designed to provide similar effectiveness with potentially less frequent dosing for improved patient convenience.

When will Jakafi XR be available to patients?

While FDA approval has been granted, Incyte has not yet announced the specific commercial launch date. Patients should consult with their healthcare providers about availability and timing.

Who is eligible for Jakafi XR treatment?

Jakafi XR is approved for adults with intermediate- or high-risk myelofibrosis, adults with polycythemia vera who haven’t responded adequately to hydroxyurea, and patients aged 12 and older with steroid-refractory graft-versus-host disease.